anti-PD-1 or PD-L1 antibody

COMBINATION_PRODUCT2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Head and Neck Cancer

Phase 2

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy

RecruitingNCT05777824

Cancer Institute and Hospital, Chinese Academy of Medical SciencesHead and Neck Cancer

Start: 2023-01-01End: 2027-12-30Target: 84Updated: 2023-10-11

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

RecruitingNCT06345287

Cancer Institute and Hospital, Chinese Academy of Medical SciencesHead and Neck Cancer

Start: 2024-01-01End: 2026-12-31Target: 133Updated: 2024-04-03